A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: Fulvestrant
Sponsor: AstraZeneca